Study of DITPA in Patients With Congestive Heart Failure
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of DITPA relative to placebo in patients with
New York Heart Association (NYHA) class III or IV congestive heart failure (CHF) who have low
serum T3. DITPA is an investigational agent.